VTR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.52B

+18.34%

0.099

-23.95%

1.55B

+14%

0.110

+10.39%

1.59B

+11.58%

0.149

-0.58%

Estimates Revision

The market is revising Upward the revenue expectations for Ventas, Inc. (VTR) for FY2025, with the revenue forecasts being adjusted by 1.74% over the past three months. During the same period, the stock price has changed by 10.59%.

Revenue Estimates for FY2025

Revise Upward

+1.74%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+8.03%

In Past 3 Month

Stock Price

Go Up

+10.59%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast VTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTR is 82.00 USD with a low forecast of 73.00 USD and a high forecast of 91.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

3 Hold

0 Sell

Strong Buy

Current: 0.000

Low

73.00

Averages

82.00

High

91.00

Current: 0.000

Low

73.00

Averages

82.00

High

91.00

Goldman Sachs

analyst

Buy

initiated

$94

2026-01-09

New

Reason

Goldman Sachs

analyst

Price Target

$94

2026-01-09

New

initiated

Buy

Reason

Goldman Sachs initiated coverage of Ventas with a Buy rating and $94 price target. Channel checks and modeling point to meaningful upside in senior housing occupancy, RevPOR, and margins, though gains are likely capped longer term by vacancy, affordability, and supply, while also improving cash flow visibility for NNN structures and senior housing REIT investment opportunities, the analyst tells investors in a research note. In contrast, lab space demand is expected to recover slowly into 2027, and Ventas' strategic shift toward greater SHOP exposure positions it to capture uncapped operating NOI upside versus traditional triple-net leases, the firm says.

Cantor Fitzgerald

NULL -> Overweight

upgrade

$85 -> $93

2026-01-05

New

Reason

Cantor Fitzgerald

Price Target

$85 -> $93

2026-01-05

New

upgrade

NULL -> Overweight

Reason

Cantor Fitzgerald raised the firm's price target on Ventas to $93 from $85 and keeps an Overweight rating on the shares. U.S. equity REITs returned 2.9% in 2025, lagging the S&P 500, but 2026 may offer optimism with a potentially more supportive macro environment and an accelerating M&A theme, the analyst tells investors in a research note. Stable supply and demand fundamentals, balance sheet strength, and a well-covered, growing 4% dividend yield make the sector attractive despite past underperformance, Cantor adds.

Jefferies

Buy

maintain

$85 -> $93

2025-12-15

Reason

Jefferies

Price Target

$85 -> $93

2025-12-15

maintain

Buy

Reason

Jefferies raised the firm's price target on Ventas to $93 from $85 and keeps a Buy rating on the shares as part of a broader research note previewing 2026 for Healthcare REITs. The firm expects another challenging year for lab landlords as elevated market vacancy and a 9.6% decline in trailing-12-month biotech funding will drive below-average retention in 2026, the analyst tells investors in a research note. For Ventas, Jefferies notes that Senior Housing net operating income growth should be among the strongest across the REIT sector, as COVID-19 and an elevated cost of capital have slowed new construction, while demographic tailwinds continue to strengthen as the Baby Boomers age into the 80+ demographic.

KeyBanc

Austin Wurschmidt

Overweight

maintain

$70 -> $85

2025-12-04

Reason

KeyBanc

Austin Wurschmidt

Price Target

$70 -> $85

2025-12-04

maintain

Overweight

Reason

KeyBanc analyst Austin Wurschmidt raised the firm's price target on Ventas to $85 from $70 and keeps an Overweight rating on the shares. The firm continues to favor Healthcare REITs with exposure to above-average growth in senior housing operating fundamentals, and investment pipelines that support accretive external growth. While KeyBanc is incrementally constructive on companies with growing Senior Housing Operating Portfolio exposure, earnings accretion, available dry powder and operating execution may be key to gain investor confidence. The firm also expects skilled nursing fundamentals to remain attractive in 2026 but continues to monitor the reimbursement backdrop following the elimination of enhanced FMAP funding, but view rent coverage levels to be relatively healthy.

Wells Fargo

Overweight

maintain

$80 -> $88

2025-11-25

Reason

Wells Fargo

Price Target

$80 -> $88

2025-11-25

maintain

Overweight

Reason

Wells Fargo raised the firm's price target on Ventas to $88 from $80 and keeps an Overweight rating on the shares. The firm says that despite a few high-profile exceptions, most REITs delivered Q3 2025 earnings and outlooks reflecting healthy operating conditions despite macro and labor market concerns.

BofA

Jeffrey Spector

Buy

upgrade

$84 -> $91

2025-11-17

Reason

BofA

Jeffrey Spector

Price Target

$84 -> $91

2025-11-17

upgrade

Buy

Reason

BofA analyst Jeffrey Spector raised the firm's price target on Ventas to $91 from $84 and keeps a Buy rating on the shares. While stock performance did not reflect it, Q3 earnings season was "strong" for U.S. REITs as 69% of REITs beat the Street, the analyst tells investors in a note on the group.

Valuation Metrics

The current forward P/E ratio for Ventas Inc (VTR.N) is 148.88, compared to its 5-year average forward P/E of -473.73. For a more detailed relative valuation and DCF analysis to assess Ventas Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-473.73

Current PE

148.88

Overvalued PE

2398.85

Undervalued PE

-3346.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

18.71

Current EV/EBITDA

20.63

Overvalued EV/EBITDA

20.28

Undervalued EV/EBITDA

17.14

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.79

Current PS

5.64

Overvalued PS

5.52

Undervalued PS

4.07

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 274.02% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 274.02% over the last month.

Sold

Bought

VTR News & Events

Events Timeline

No data

News

6.0

01-09CNBC

Goldman Sachs Initiates Buy on Ventas and Omega Healthcare with Significant Upside Potential

3.5

2025-12-30CNBC

Elbit Systems Delivers First Laser Defense System, Stock Doubles

6.5

2025-12-19CNBC

Jefferies' Leading Real Estate Investment for 2026 Targets Aging Population and Offers Strong Dividends

People Also Watch

Frequently Asked Questions

What is Ventas Inc (VTR) stock price today?

The current price of VTR is 74.9 USD — it has decreased -0.24 % in the last trading day.

What is Ventas Inc (VTR)'s business?

Ventas, Inc. is a real estate investment trust (REIT). The Company holds a portfolio that includes senior housing communities, outpatient medical buildings, research centers, hospitals and healthcare facilities located in North America and the United Kingdom. The Company owns approximately 1,400 properties in North America and the United Kingdom. It operates in three segments: senior housing operating portfolio (SHOP), outpatient medical and research portfolio (OM&R), and triple-net leased properties (NNN). In its SHOP segment, it owns and invests in senior housing communities. It engages third-party managers to operate the communities on its behalf. In its OM&R segment, it primarily acquires, owns, develops, leases and manages outpatient medical buildings and research centers. In its NNN segment, it invests in and owns senior housing communities, skilled nursing facilities (SNFs), long-term acute care facilities (LTACs), and freestanding inpatient rehabilitation facilities (IRFs).

What is the price predicton of VTR Stock?

What is Ventas Inc (VTR)'s revenue for the last quarter?

Ventas Inc revenue for the last quarter amounts to 1.49B USD, increased 20.44 % YoY.

What is Ventas Inc (VTR)'s earnings per share (EPS) for the last quarter?

Ventas Inc. EPS for the last quarter amounts to 0.14 USD, increased 180.00 % YoY.

What changes have occurred in the market's expectations for Ventas Inc (VTR)'s fundamentals?

How many employees does Ventas Inc (VTR). have?

Ventas Inc (VTR) has 498 emplpoyees as of January 10 2026.

What is Ventas Inc (VTR) market cap?

Today VTR has the market capitalization of 35.18B USD.